Synergy Spine Solutions Touts Rapid Adoption of its Artificial Cervical Disc

Synergy Spine Solutions announced today that its Synergy Disc has been used successfully in 100 U.S. cervical disc replacement surgeries within 100 days of its first commercial procedure, following U.S. Food and Drug Administration (FDA) approval earlier this year.

The milestone reflects widespread surgeon adoption of the Synergy Disc, reportedly the first and only artificial cervical disc that intentionally preserves motion while improving anatomic alignment, according to executives. The device features a six-degree lordotic core to restore the spine’s natural curve, and is made from a nickel-free titanium alloy, helping reduce a potential barrier for patients with nickel sensitivities or allergies. Nickel allergy is among the most common metal allergies, with published estimates suggesting that up to 17% of women and 3% of men are allergic to nickel.

“For years, our focus has been on preserving motion because that is fundamental to healthy cervical spine function,” said Dr. Todd Lanman, a spinal neurosurgeon who participated in the Synergy Disc (1-Level) IDE trial and performed the first U.S. commercial Synergy Disc procedure. “As cervical disc replacement continues to evolve, we’re also recognizing the importance of restoring cervical alignment. Synergy combines motion preservation with alignment restoration to better replicate the spine’s natural biomechanics.”

Before receiving U.S. approval for use, the Synergy Disc had been used for more than 10 years in 10-plus countries and implanted in thousands of patients. Clinical data from the company’s U.S. Investigational Device Exemption study showed that the Synergy Disc achieved an 87.1% composite clinical success rate at 24 months, demonstrating superiority to anterior cervical discectomy and fusion, a long-standing traditional treatment for cervical degenerative disc disease. Patients treated with the Synergy Disc also reported lower neck and arm pain scores and higher overall satisfaction compared to the ACDF control group. 

“The clinical data behind the Synergy Disc supports what is intuitive to surgeons: cervical disc replacement must preserve motion while also restoring alignment,” Synergy Spine Solutions Chief Medical Officer Neil Duggal, M.D., stated. “As more surgeons evaluate cervical disc replacement options, alignment is becoming a central part of the conversation.”

Across the 100 U.S. procedures, surgeons voluntarily selected the six-degree lordotic core option in 98% of cases. This strong surgeon preference reinforces the clinical importance of restoring alignment in addition to preserving motion. Earlier this year, the Synergy Disc received FDA Premarket Approval for 1-level indications at C3-C7.

Developed in close collaboration with spine surgeons, the Synergy Disc is built from time-tested orthopedic materials chosen to make procedures as safe, predictable, and reliable as possible. The device reflects a patient-first philosophy prioritizing surgical consistency, clear MRI-compatible postoperative imaging, and helping patients reclaim their quality of life.

“Reaching 100 U.S. cases within 100 days of our first commercial procedure reflects the strong early adoption of our technology and the growing demand among surgeons for cervical disc replacement solutions designed to support both motion and alignment,” Synergy Spine Solutions Chief Commercial Officer Troy Wahlenmaier commented. “Our focus remains on scaling thoughtfully—supporting surgeons throughout the rollout while expanding access to a technology backed by more than a decade of international clinical experience.”

Synergy Spine Solutions is a medical device company developing motion-preserving technologies to treat degenerative disc disease while supporting the spine’s natural curvature. Its flagship product, the FDA-approved Synergy Disc, features a built-in six-degree lordotic core designed to preserve motion and improve sagittal alignment.